SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 11/04/22 AbbVie Inc. 10-Q 9/30/22 74:16M |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 2.84M 2: EX-10.2 Material Contract HTML 70K 3: EX-31.1 Certification -- §302 - SOA'02 HTML 24K 4: EX-31.2 Certification -- §302 - SOA'02 HTML 25K 5: EX-32.1 Certification -- §906 - SOA'02 HTML 22K 6: EX-32.2 Certification -- §906 - SOA'02 HTML 22K 12: R1 Document and Entity Information HTML 100K 13: R2 Condensed Consolidated Statements of Earnings HTML 110K (Unaudited) 14: R3 Condensed Consolidated Statements of Comprehensive HTML 61K Income (Unaudited) 15: R4 Condensed Consolidated Statements of Comprehensive HTML 31K Income (Parenthetical) (Unaudited) 16: R5 Condensed Consolidated Balance Sheets HTML 130K 17: R6 Condensed Consolidated Balance Sheets HTML 29K (Parenthetical) 18: R7 Condensed Consolidated Statements of Equity HTML 89K (Unaudited) 19: R8 Condensed Consolidated Statements of Cash Flows HTML 118K (Unaudited) 20: R9 Basis of Presentation HTML 25K 21: R10 Supplemental Financial Information HTML 45K 22: R11 Earnings Per Share HTML 58K 23: R12 Licensing, Acquisitions and Other Arrangements HTML 29K 24: R13 Collaborations HTML 49K 25: R14 Goodwill and Intangible Assets HTML 49K 26: R15 Integration and Restructuring Plans HTML 61K 27: R16 Financial Instruments and Fair Value Measures HTML 208K 28: R17 Post-Employment Benefits HTML 54K 29: R18 Equity HTML 126K 30: R19 Income Taxes HTML 26K 31: R20 Legal Proceedings and Contingencies HTML 42K 32: R21 Segment Information HTML 189K 33: R22 Supplemental Financial Information (Tables) HTML 50K 34: R23 Earnings Per Share (Tables) HTML 56K 35: R24 Collaborations (Tables) HTML 46K 36: R25 Goodwill and Intangible Assets (Tables) HTML 75K 37: R26 Integration and Restructuring Plans (Tables) HTML 66K 38: R27 Financial Instruments and Fair Value Measures HTML 220K (Tables) 39: R28 Post-Employment Benefits (Tables) HTML 53K 40: R29 Equity (Tables) HTML 127K 41: R30 Segment Information (Tables) HTML 183K 42: R31 Basis of Presentation (Details) HTML 24K 43: R32 Supplemental Financial Information (Details) HTML 53K 44: R33 Earnings Per Share (Details) HTML 72K 45: R34 Licensing, Acquisitions and Other Arrangements HTML 67K (Details) 46: R35 Collaborations (Details) HTML 55K 47: R36 Goodwill and Intangible Assets - Goodwill HTML 31K (Details) 48: R37 Goodwill and Intangible Assets - Intangible HTML 48K Assets, Net (Details) 49: R38 Integration and Restructuring Plans (Details) HTML 59K 50: R39 Financial Instruments and Fair Value Measures - HTML 94K Financial Instruments (Details) 51: R40 Financial Instruments and Fair Value Measures - HTML 70K Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) 52: R41 Financial Instruments and Fair Value Measures - HTML 80K Fair Value Measures (Details) 53: R42 Financial Instruments and Fair Value Measures - HTML 50K Significant Level 3 Unobservable Inputs (Details) 54: R43 Financial Instruments and Fair Value Measures - HTML 42K Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) 55: R44 Financial Instruments and Fair Value Measures - HTML 47K Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) 56: R45 Financial Instruments and Fair Value Measures - HTML 35K Concentrations of Risk (Details) 57: R46 Financial Instruments and Fair Value Measures - HTML 70K Debt and Credit Facilities (Details) 58: R47 Post-Employment Benefits (Details) HTML 45K 59: R48 Equity - Stock-Based Compensation (Details) HTML 35K 60: R49 Equity - Stock Options (Details) HTML 31K 61: R50 Equity - RSUs and Performance Shares (Details) HTML 32K 62: R51 Equity - Cash Dividends (Details) HTML 26K 63: R52 Equity - Stock Repurchase Program (Details) HTML 31K 64: R53 Equity - Accumulated Other Comprehensive Loss HTML 66K (Details) 65: R54 Equity - Amounts Reclassified Out Of Accumulated HTML 75K Other Comprehensive Loss (Details) 66: R55 Income Taxes (Details) HTML 28K 67: R56 Legal Proceedings and Contingencies (Details) HTML 64K 68: R57 Segment Information - Additional Information HTML 23K (Details) 69: R58 Segment Information - Disaggregation of Revenue HTML 137K (Details) 72: XML IDEA XML File -- Filing Summary XML 131K 70: XML XBRL Instance -- abbv-20220930_htm XML 4.06M 71: EXCEL IDEA Workbook of Financial Reports XLSX 145K 8: EX-101.CAL XBRL Calculations -- abbv-20220930_cal XML 199K 9: EX-101.DEF XBRL Definitions -- abbv-20220930_def XML 687K 10: EX-101.LAB XBRL Labels -- abbv-20220930_lab XML 1.72M 11: EX-101.PRE XBRL Presentations -- abbv-20220930_pre XML 993K 7: EX-101.SCH XBRL Schema -- abbv-20220930 XSD 161K 73: JSON XBRL Instance as JSON Data -- MetaLinks 436± 654K 74: ZIP XBRL Zipped Folder -- 0001551152-22-000045-xbrl Zip 532K
abbv-20220930 |
(Exact name of registrant as specified in its charter) | ||||||||
i Delaware | i 32-0375147 | |||||||
(State or other jurisdiction of incorporation or organization) | (I.R.S. employer identification number) |
i Large
Accelerated Filer | ☒ | Accelerated Filer | ☐ | ||||||||
Non-Accelerated Filer | ☐ | Smaller reporting company | i ☐ | ||||||||
Emerging growth company | i ☐ |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
i i Common Stock, par value $0.01 per share / | i i ABBV / | i New York Stock Exchange | ||||||||||||
i Chicago Stock Exchange | ||||||||||||||
i 1.500% Senior Notes due 2023 | i ABBV23B | i New York Stock Exchange | ||||||||||||
i 1.375% Senior Notes due 2024 | i ABBV24 | i New York Stock Exchange | ||||||||||||
i 1.250% Senior Notes due 2024 | i ABBV24B | i New York Stock Exchange | ||||||||||||
i 0.750% Senior Notes due 2027 | i ABBV27 | i New York Stock Exchange | ||||||||||||
i 2.125% Senior Notes due 2028 | i ABBV28 | i New York Stock Exchange | ||||||||||||
i 2.625% Senior Notes due 2028 | i ABBV28B | i New York Stock Exchange | ||||||||||||
i 2.125% Senior Notes due 2029 | i ABBV29 | i New York Stock Exchange | ||||||||||||
i 1.250% Senior Notes due 2031 | i ABBV31 | i New York Stock Exchange |
Page | ||||||||
Three
months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||
(in millions, except per share data) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Net revenues | $ | i 14,812 | $ | i 14,342 | $ | i 42,933 | $ | i 41,311 | ||||||||||||||||||
Cost of products sold | i 5,022 | i 4,390 | i 13,244 | i 13,126 | ||||||||||||||||||||||
Selling, general and administrative | i 3,304 | i 3,083 | i 11,843 | i 9,089 | ||||||||||||||||||||||
Research and development | i 1,614 | i 1,661 | i 4,720 | i 5,095 | ||||||||||||||||||||||
Acquired IPR&D and milestones | i 40 | i 402 | i 454 | i 719 | ||||||||||||||||||||||
Other operating expense, net | i 229 | i 500 | i 57 | i 432 | ||||||||||||||||||||||
Total operating costs and expenses | i 10,209 | i 10,036 | i 30,318 | i 28,461 | ||||||||||||||||||||||
Operating earnings | i 4,603 | i 4,306 | i 12,615 | i 12,850 | ||||||||||||||||||||||
Interest expense, net | i 497 | i 585 | i 1,568 | i 1,813 | ||||||||||||||||||||||
Net foreign exchange loss | i 36 | i 12 | i 108 | i 35 | ||||||||||||||||||||||
Other expense (income), net | ( i 330) | i 21 | i 427 | i 2,284 | ||||||||||||||||||||||
Earnings before income tax expense | i 4,400 | i 3,688 | i 10,512 | i 8,718 | ||||||||||||||||||||||
Income tax expense | i 448 | i 508 | i 1,139 | i 1,214 | ||||||||||||||||||||||
Net earnings | i 3,952 | i 3,180 | i 9,373 | i 7,504 | ||||||||||||||||||||||
Net earnings attributable to noncontrolling interest | i 3 | i 1 | i 10 | i 6 | ||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | $ | i 3,949 | $ | i 3,179 | $ | i 9,363 | $ | i 7,498 | ||||||||||||||||||
Per share data | ||||||||||||||||||||||||||
Basic earnings per share attributable to AbbVie Inc. | $ | i 2.22 | $ | i 1.78 | $ | i 5.26 | $ | i 4.21 | ||||||||||||||||||
Diluted earnings per share attributable to AbbVie Inc. | $ | i 2.21 | $ | i 1.78 | $ | i 5.24 | $ | i 4.19 | ||||||||||||||||||
Weighted-average basic shares outstanding | i 1,771 | i 1,770 | i 1,771 | i 1,769 | ||||||||||||||||||||||
Weighted-average diluted shares outstanding | i 1,776 | i 1,777 | i 1,777 | i 1,776 |
2022 Form 10-Q | | 1 |
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Net earnings | $ | i 3,952 | $ | i 3,180 | $ | i 9,373 | $ | i 7,504 | |||||||||||||||
Foreign
currency translation adjustments, net of tax expense (benefit) of $( i 11) for the three months and $( i 30)
for the nine months ended September 30, 2022 and $( i 8) for the three months and $( i 32)
for the nine months ended September 30, 2021 | ( i 989) | ( i 361) | ( i 2,043) | ( i 794) | |||||||||||||||||||
Net
investment hedging activities, net of tax expense (benefit) of $ i 165 for the three months and $ i 348 for the nine months ended September
30, 2022 and $ i 51 for the three months and $ i 123 for the nine months ended September 30, 2021 | i 599 | i 184 | i 1,265 | i 444 | |||||||||||||||||||
Pension
and post-employment benefits, net of tax expense (benefit) of $ i 14 for the three months and $ i 35
for the nine months ended September 30, 2022 and $ i 17 for the three months and $ i 50
for the nine months ended September 30, 2021 | i 60 | i 67 | i 136 | i 196 | |||||||||||||||||||
Cash
flow hedging activities, net of tax expense (benefit) of $ i 14 for the three months and $ i 17
for the nine months ended September 30, 2022 and $ i 13 for the three months and $ i 16
for the nine months ended September 30, 2021 | i 83 | i 57 | i 98 | i 115 | |||||||||||||||||||
Other comprehensive loss | ( i 247) | ( i 53) | ( i 544) | ( i 39) | |||||||||||||||||||
Comprehensive income | i 3,705 | i 3,127 | i 8,829 | i 7,465 | |||||||||||||||||||
Comprehensive income attributable to noncontrolling interest | i 3 | i 1 | i 10 | i 6 | |||||||||||||||||||
Comprehensive income attributable to AbbVie Inc. | $ | i 3,702 | $ | i 3,126 | $ | i 8,819 | $ | i 7,459 |
2022 Form 10-Q | | 2 |
(in millions, except share data) | September 30, 2022 | December 31, 2021 | |||||||||
(unaudited) | |||||||||||
Assets | |||||||||||
Current assets | |||||||||||
Cash and equivalents | $ | i 11,832 | $ | i 9,746 | |||||||
Short-term investments | i 47 | i 84 | |||||||||
Accounts receivable, net | i 10,743 | i 9,977 | |||||||||
Inventories | i 3,172 | i 3,128 | |||||||||
Prepaid expenses and other | i 4,570 | i 4,993 | |||||||||
Total current assets | i 30,364 | i 27,928 | |||||||||
Investments | i 235 | i 277 | |||||||||
Property and equipment, net | i 4,893 | i 5,110 | |||||||||
Intangible assets, net | i 68,725 | i 75,951 | |||||||||
Goodwill | i 31,726 | i 32,379 | |||||||||
Other assets | i 5,382 | i 4,884 | |||||||||
Total assets | $ | i 141,325 | $ | i 146,529 | |||||||
Liabilities and Equity | |||||||||||
Current liabilities | |||||||||||
Short-term borrowings | $ | i 10 | $ | i 14 | |||||||
Current portion of long-term debt and finance lease obligations | i 9,197 | i 12,481 | |||||||||
Accounts payable and accrued liabilities | i 23,505 | i 22,699 | |||||||||
Total current liabilities | i 32,712 | i 35,194 | |||||||||
Long-term debt and finance lease obligations | i 60,399 | i 64,189 | |||||||||
Deferred income taxes | i 1,972 | i 3,009 | |||||||||
Other long-term liabilities | i 30,215 | i 28,701 | |||||||||
Commitments and contingencies | i | i | |||||||||
Stockholders' equity | |||||||||||
Common stock, $ i i 0.01 /
par value, i i 4,000,000,000 / shares authorized,
i 1,812,973,038 shares issued as of September 30, 2022 and i 1,803,195,293 as of December 31,
2021 | i 18 | i 18 | |||||||||
Common
stock held in treasury, at cost, i 44,572,117 shares as of September 30, 2022 and i 34,857,597 as of December 31,
2021 | ( i 4,590) | ( i 3,143) | |||||||||
Additional paid-in capital | i 19,056 | i 18,305 | |||||||||
Retained earnings | i 4,953 | i 3,127 | |||||||||
Accumulated other comprehensive loss | ( i 3,443) | ( i 2,899) | |||||||||
Total stockholders' equity | i 15,994 | i 15,408 | |||||||||
Noncontrolling interest | i 33 | i 28 | |||||||||
Total equity | i 16,027 | i 15,436 | |||||||||
Total liabilities and equity | $ | i 141,325 | $ | i 146,529 |
2022 Form 10-Q | | 3 |
(in millions) | Common shares outstanding | Common stock | Treasury stock | Additional paid-in capital | Retained earnings | Accumulated other comprehensive loss | Noncontrolling interest | Total | |||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2021 | i 1,767 | $ | i 18 | $ | ( i 3,022) | $ | i 17,936 | $ | i 740 | $ | ( i 3,103) | $ | i 25 | $ | i 12,594 | ||||||||||||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | — | i — | i — | i — | i 3,179 | i — | i — | i 3,179 | |||||||||||||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | — | i — | i — | i — | i — | ( i 53) | i — | ( i 53) | |||||||||||||||||||||||||||||||||||||||
Dividends declared | — | i — | i — | i — | ( i 2,319) | i — | i — | ( i 2,319) | |||||||||||||||||||||||||||||||||||||||
Purchases of treasury stock | i — | i — | ( i 6) | i — | i — | i — | i — | ( i 6) | |||||||||||||||||||||||||||||||||||||||
Stock-based compensation plans and other | i 1 | i — | i 8 | i 172 | i — | i — | i — | i 180 | |||||||||||||||||||||||||||||||||||||||
Change in noncontrolling interest | — | i — | i — | i — | i — | i — | i 2 | i 2 | |||||||||||||||||||||||||||||||||||||||
Balance at September 30, 2021 | i 1,768 | $ | i 18 | $ | ( i 3,020) | $ | i 18,108 | $ | i 1,600 | $ | ( i 3,156) | $ | i 27 | $ | i 13,577 | ||||||||||||||||||||||||||||||||
Balance at June 30, 2022 | i 1,768 | $ | i 18 | $ | ( i 4,591) | $ | i 18,906 | $ | i 3,516 | $ | ( i 3,196) | $ | i 35 | $ | i 14,688 | ||||||||||||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | — | i — | i — | i — | i 3,949 | i — | i — | i 3,949 | |||||||||||||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | — | i — | i — | i — | i — | ( i 247) | i — | ( i 247) | |||||||||||||||||||||||||||||||||||||||
Dividends declared | — | i — | i — | i — | ( i 2,512) | i — | i — | ( i 2,512) | |||||||||||||||||||||||||||||||||||||||
Purchases of treasury stock | i — | i — | ( i 4) | i — | i — | i — | i — | ( i 4) | |||||||||||||||||||||||||||||||||||||||
Stock-based compensation plans and other | i — | i — | i 5 | i 150 | i — | i — | i — | i 155 | |||||||||||||||||||||||||||||||||||||||
Change in noncontrolling interest | — | i — | i — | i — | i — | i — | ( i 2) | ( i 2) | |||||||||||||||||||||||||||||||||||||||
Balance at September 30, 2022 | i 1,768 | $ | i 18 | $ | ( i 4,590) | $ | i 19,056 | $ | i 4,953 | $ | ( i 3,443) | $ | i 33 | $ | i 16,027 | ||||||||||||||||||||||||||||||||
Balance at December 31, 2020 | i 1,765 | $ | i 18 | $ | ( i 2,264) | $ | i 17,384 | $ | i 1,055 | $ | ( i 3,117) | $ | i 21 | $ | i 13,097 | ||||||||||||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | — | i — | i — | i — | i 7,498 | i — | i — | i 7,498 | |||||||||||||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | — | i — | i — | i — | i — | ( i 39) | i — | ( i 39) | |||||||||||||||||||||||||||||||||||||||
Dividends declared | — | i — | i — | i — | ( i 6,953) | i — | i — | ( i 6,953) | |||||||||||||||||||||||||||||||||||||||
Purchases of treasury stock | ( i 7) | i — | ( i 803) | i — | i — | i — | i — | ( i 803) | |||||||||||||||||||||||||||||||||||||||
Stock-based compensation plans and other | i 10 | i — | i 47 | i 724 | i — | i — | i — | i 771 | |||||||||||||||||||||||||||||||||||||||
Change in noncontrolling interest | — | i — | i — | i — | i — | i — | i 6 | i 6 | |||||||||||||||||||||||||||||||||||||||
Balance at September 30, 2021 | i 1,768 | $ | i 18 | $ | ( i 3,020) | $ | i 18,108 | $ | i 1,600 | $ | ( i 3,156) | $ | i 27 | $ | i 13,577 | ||||||||||||||||||||||||||||||||
Balance at December 31, 2021 | i 1,768 | $ | i 18 | $ | ( i 3,143) | $ | i 18,305 | $ | i 3,127 | $ | ( i 2,899) | $ | i 28 | $ | i 15,436 | ||||||||||||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | — | i — | i — | i — | i 9,363 | i — | i — | i 9,363 | |||||||||||||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | — | i — | i — | i — | i — | ( i 544) | i — | ( i 544) | |||||||||||||||||||||||||||||||||||||||
Dividends declared | — | i — | i — | i — | ( i 7,537) | i — | i — | ( i 7,537) | |||||||||||||||||||||||||||||||||||||||
Purchases of treasury stock | ( i 10) | i — | ( i 1,483) | i — | i — | i — | i — | ( i 1,483) | |||||||||||||||||||||||||||||||||||||||
Stock-based compensation plans and other | i 10 | i — | i 36 | i 751 | i — | i — | i — | i 787 | |||||||||||||||||||||||||||||||||||||||
Change in noncontrolling interest | — | i — | i — | i — | i — | i — | i 5 | i 5 | |||||||||||||||||||||||||||||||||||||||
Balance at September 30, 2022 | i 1,768 | $ | i 18 | $ | ( i 4,590) | $ | i 19,056 | $ | i 4,953 | $ | ( i 3,443) | $ | i 33 | $ | i 16,027 |
2022 Form 10-Q | | 4 |
Nine months ended September 30, | |||||||||||
(in millions) (brackets denote cash outflows) | 2022 | 2021 | |||||||||
Cash flows from operating activities | |||||||||||
Net earnings | $ | i 9,373 | $ | i 7,504 | |||||||
Adjustments to reconcile net earnings to net cash from operating activities: | |||||||||||
Depreciation | i 582 | i 630 | |||||||||
Amortization of intangible assets | i 5,728 | i 5,912 | |||||||||
Deferred income taxes | ( i 1,415) | ( i 153) | |||||||||
Change in fair value of contingent consideration liabilities | i 647 | i 2,447 | |||||||||
Stock-based compensation | i 539 | i 563 | |||||||||
Acquired IPR&D and milestones | i 454 | i 719 | |||||||||
Other charges related to collaborations | i — | i 500 | |||||||||
Gain on divestitures | ( i 172) | ( i 68) | |||||||||
Non-cash litigation reserve adjustments, net of cash payments | i 2,261 | i 21 | |||||||||
Impairment of intangible assets | i 770 | i 50 | |||||||||
Other, net | ( i 151) | ( i 185) | |||||||||
Changes in operating assets and liabilities, net of acquisitions: | |||||||||||
Accounts receivable | ( i 1,039) | ( i 572) | |||||||||
Inventories | ( i 516) | ( i 30) | |||||||||
Prepaid expenses and other assets | ( i 60) | ( i 462) | |||||||||
Accounts payable and other liabilities | i 330 | i 1,454 | |||||||||
Income tax assets and liabilities, net | i 184 | ( i 628) | |||||||||
Cash flows from operating activities | i 17,515 | i 17,702 | |||||||||
Cash flows from investing activities | |||||||||||
Acquisitions and investments | ( i 494) | ( i 837) | |||||||||
Acquisitions of property and equipment | ( i 482) | ( i 600) | |||||||||
Purchases of investment securities | ( i 1,428) | ( i 73) | |||||||||
Sales and maturities of investment securities | i 1,460 | i 88 | |||||||||
Other, net | i 769 | i 223 | |||||||||
Cash flows from investing activities | ( i 175) | ( i 1,199) | |||||||||
Cash flows from financing activities | |||||||||||
Proceeds from issuance of long-term debt | i 2,000 | i 1,000 | |||||||||
Repayments of long-term debt and finance lease obligations | ( i 7,582) | ( i 5,662) | |||||||||
Dividends paid | ( i 7,537) | ( i 6,947) | |||||||||
Purchases of treasury stock | ( i 1,483) | ( i 803) | |||||||||
Proceeds from the exercise of stock options | i 209 | i 169 | |||||||||
Payments of contingent consideration liabilities | ( i 817) | ( i 480) | |||||||||
Other, net | i 41 | i 22 | |||||||||
Cash flows from financing activities | ( i 15,169) | ( i 12,701) | |||||||||
Effect of exchange rate changes on cash and equivalents | ( i 85) | ( i 69) | |||||||||
Net change in cash and equivalents | i 2,086 | i 3,733 | |||||||||
Cash and equivalents, beginning of period | i 9,746 | i 8,449 | |||||||||
Cash and equivalents, end of period | $ | i 11,832 | $ | i 12,182 | |||||||
2022 Form 10-Q | | 5 |
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Interest expense | $ | i 560 | $ | i 596 | $ | i 1,664 | $ | i 1,843 | ||||||||||||||||||
Interest income | ( i 63) | ( i 11) | ( i 96) | ( i 30) | ||||||||||||||||||||||
Interest expense, net | $ | i 497 | $ | i 585 | $ | i 1,568 | $ | i 1,813 |
(in millions) | September
30, 2022 | December 31, 2021 | |||||||||
Finished goods | $ | i 903 | $ | i 932 | |||||||
Work-in-process | i 1,309 | i 1,193 | |||||||||
Raw materials | i 960 | i 1,003 | |||||||||
Inventories | $ | i 3,172 | $ | i 3,128 |
2022
Form 10-Q | | 6 |
(in millions) | September
30, 2022 | December 31, 2021 | |||||||||
Property and equipment, gross | $ | i 10,679 | $ | i 10,727 | |||||||
Accumulated depreciation | ( i 5,786) | ( i 5,617) | |||||||||
Property and equipment, net | $ | i 4,893 | $ | i 5,110 |
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||
(in millions, except per share data) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Basic EPS | ||||||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | $ | i 3,949 | $ | i 3,179 | $ | i 9,363 | $ | i 7,498 | ||||||||||||||||||
Earnings allocated to participating securities | i 18 | i 21 | i 43 | i 53 | ||||||||||||||||||||||
Earnings available to common shareholders | $ | i 3,931 | $ | i 3,158 | $ | i 9,320 | $ | i 7,445 | ||||||||||||||||||
Weighted-average basic shares outstanding | i 1,771 | i 1,770 | i 1,771 | i 1,769 | ||||||||||||||||||||||
Basic earnings per share attributable to AbbVie Inc. | $ | i 2.22 | $ | i 1.78 | $ | i 5.26 | $ | i 4.21 | ||||||||||||||||||
Diluted EPS | ||||||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | $ | i 3,949 | $ | i 3,179 | $ | i 9,363 | $ | i 7,498 | ||||||||||||||||||
Earnings allocated to participating securities | i 18 | i 21 | i 43 | i 53 | ||||||||||||||||||||||
Earnings available to common shareholders | $ | i 3,931 | $ | i 3,158 | $ | i 9,320 | $ | i 7,445 | ||||||||||||||||||
Weighted-average shares of common stock outstanding | i 1,771 | i 1,770 | i 1,771 | i 1,769 | ||||||||||||||||||||||
Effect of dilutive securities | i 5 | i 7 | i 6 | i 7 | ||||||||||||||||||||||
Weighted-average diluted shares outstanding | i 1,776 | i 1,777 | i 1,777 | i 1,776 | ||||||||||||||||||||||
Diluted earnings per share attributable to AbbVie Inc. | $ | i 2.21 | $ | i 1.78 | $ | i 5.24 | $ | i 4.19 |
2022 Form 10-Q | | 7 |
2022 Form 10-Q | | 8 |
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
United States - Janssen's share of profits (included in cost of products sold) | $ | i 398 | $ | i 518 | $ | i 1,210 | $ | i 1,497 | ||||||||||||||||||
International - AbbVie's share of profits (included in net revenues) | i 286 | i 265 | i 868 | i 816 | ||||||||||||||||||||||
Global - AbbVie's share of other costs (included in respective line items) | i 63 | i 76 | i 196 | i 220 |
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Genentech's share of profits, including royalties (included in cost of products sold) | $ | i 204 | $ | i 187 | $ | i 578 | $ | i 514 | ||||||||||||||||||
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) | i 10 | i 10 | i 27 | i 29 | ||||||||||||||||||||||
AbbVie's share of development costs (included in R&D) | i 29 | i 34 | i 87 | i 110 |
2022
Form 10-Q | | 9 |
(in millions) | |||||
Balance as of December 31, 2021 | $ | i 32,379 | |||
Foreign currency translation adjustments | ( i 653) | ||||
Balance as of September 30, 2022 | $ | i 31,726 |
September 30, 2022 | December 31, 2021 | ||||||||||||||||||||||||||||||||||
(in millions) | Gross carrying amount | Accumulated amortization | Net carrying amount | Gross carrying amount | Accumulated amortization | Net carrying amount | |||||||||||||||||||||||||||||
Definite-lived intangible assets | |||||||||||||||||||||||||||||||||||
Developed product rights | $ | i 87,313 | $ | ( i 23,368) | $ | i 63,945 | $ | i 88,945 | $ | ( i 18,463) | $ | i 70,482 | |||||||||||||||||||||||
License agreements | i 8,486 | ( i 4,376) | i 4,110 | i 8,487 | ( i 3,688) | i 4,799 | |||||||||||||||||||||||||||||
Total definite-lived intangible assets | i 95,799 | ( i 27,744) | i 68,055 | i 97,432 | ( i 22,151) | i 75,281 | |||||||||||||||||||||||||||||
Indefinite-lived intangible assets | i 670 | — | i 670 | i 670 | — | i 670 | |||||||||||||||||||||||||||||
Total intangible assets, net | $ | i 96,469 | $ | ( i 27,744) | $ | i 68,725 | $ | i 98,102 | $ | ( i 22,151) | $ | i 75,951 |
2022 Form 10-Q | | 10 |
Severance and employee benefits | Other integration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | Three months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cost of products sold | $ | i — | $ | i 2 | $ | ( i 4) | $ | i 8 | $ | i 24 | $ | i 44 | $ | i 85 | $ | i 84 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Research and development | i 1 | i — | i 2 | i — | i 3 | i 18 | i 12 | i 87 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Selling, general and administrative | i 4 | i 18 | i 4 | i 47 | i 84 | i 88 | i 230 | i 213 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total charges | $ | i 5 | $ | i 20 | $ | i 2 | $ | i 55 | $ | i 111 | $ | i 150 | $ | i 327 | $ | i 384 |
(in millions) | Severance and employee benefits | Other integration | |||||||||
Accrued balance as of December 31, 2021 | $ | i 222 | $ | i 33 | |||||||
Charges | i 2 | i 316 | |||||||||
Payments and other adjustments | ( i 107) | ( i 343) | |||||||||
Accrued balance as of September 30, 2022 | $ | i 117 | $ | i 6 |
(in millions) | |||||
Accrued balance as of December 31, 2021 | $ | i 33 | |||
Restructuring charges | i 112 | ||||
Payments and other adjustments | ( i 25) | ||||
Accrued balance as of September 30, 2022 | $ | i 120 |
2022 Form 10-Q | | 11 |
Fair
value – Derivatives in asset position | Fair value – Derivatives in liability position | ||||||||||||||||||||||
(in millions) | Balance sheet caption | September 30, 2022 | December 31, 2021 | Balance sheet caption | September 30, 2022 | December 31, 2021 | |||||||||||||||||
Foreign currency forward exchange contracts | |||||||||||||||||||||||
Designated as cash flow hedges | Prepaid expenses and other | $ | i 153 | $ | i 51 | Accounts payable and accrued liabilities | $ | i 9 | $ | i 2 | |||||||||||||
Designated as cash flow hedges | Other assets | i 1 | i — | Other long-term liabilities | i — | i — | |||||||||||||||||
Designated as net investment hedges | Prepaid expenses and other | i 70 | i 149 | Accounts payable and accrued liabilities | i — | i — | |||||||||||||||||
Designated as net investment hedges | Other assets | i 283 | i 15 | Other long-term liabilities | i — | i — | |||||||||||||||||
Not designated as hedges | Prepaid expenses and other | i 60 | i 26 | Accounts payable and accrued liabilities | i 86 | i 13 | |||||||||||||||||
Interest rate swap contracts | |||||||||||||||||||||||
Designated as cash flow hedges | Prepaid expenses and other | i 2 | i — | Accounts payable and accrued liabilities | i — | i 7 | |||||||||||||||||
Designated as fair value hedges | Prepaid expenses and other | i — | i — | Accounts payable and accrued liabilities | i 21 | i — | |||||||||||||||||
Designated as fair value hedges | Other assets | i — | i 26 | Other long-term liabilities | i 393 | i 15 | |||||||||||||||||
Total derivatives | $ | i 569 | $ | i 267 | $ | i 509 | $ | i 37 |
2022 Form 10-Q | | 12 |
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Foreign currency forward exchange contracts | ||||||||||||||||||||||||||
Designated as cash flow hedges | $ | i 124 | $ | i 43 | $ | i 171 | $ | i 67 | ||||||||||||||||||
Designated as net investment hedges | i 362 | i 101 | i 748 | i 186 | ||||||||||||||||||||||
Interest rate swap contracts designated as cash flow hedges | i — | ( i 1) | i 6 | i — | ||||||||||||||||||||||
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||
(in millions) | Statement of earnings caption | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||||
Foreign currency forward exchange contracts | |||||||||||||||||||||||||||||
Designated as cash flow hedges | Cost of products sold | $ | i 21 | $ | ( i 28) | $ | i 47 | $ | ( i 62) | ||||||||||||||||||||
Designated as net investment hedges | Interest expense, net | i 29 | i 7 | i 67 | i 16 | ||||||||||||||||||||||||
Not designated as hedges | Net foreign exchange loss | ( i 121) | ( i 25) | ( i 285) | ( i 53) | ||||||||||||||||||||||||
Treasury rate lock agreements designated as cash flow hedges | Interest expense, net | i 6 | i 6 | i 18 | i 18 | ||||||||||||||||||||||||
Interest rate swap contracts | |||||||||||||||||||||||||||||
Designated as cash flow hedges | Interest expense, net | i — | ( i 6) | ( i 3) | ( i 20) | ||||||||||||||||||||||||
Designated as fair value hedges | Interest expense, net | ( i 141) | ( i 5) | ( i 424) | ( i 73) | ||||||||||||||||||||||||
Debt designated as hedged item in fair value hedges | Interest expense, net | i 141 | i 5 | i 424 | i 73 |
2022 Form 10-Q | | 13 |
Basis of fair value measurement | |||||||||||||||||||||||
(in millions) | Total | Quoted prices in
active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | |||||||||||||||||||
Assets | |||||||||||||||||||||||
Cash and equivalents | $ | i 11,832 | $ | i 4,303 | $ | i 7,529 | $ | i — | |||||||||||||||
Money market funds and time deposits | i 36 | i — | i 36 | i — | |||||||||||||||||||
Debt securities | i 31 | i — | i 31 | i — | |||||||||||||||||||
Equity securities | i 72 | i 50 | i 22 | i — | |||||||||||||||||||
Interest rate swap contracts | i 2 | i — | i 2 | i — | |||||||||||||||||||
Foreign currency contracts | i 567 | i — | i 567 | i — | |||||||||||||||||||
Total assets | $ | i 12,540 | $ | i 4,353 | $ | i 8,187 | $ | i — | |||||||||||||||
Liabilities | |||||||||||||||||||||||
Interest rate swap contracts | $ | i 414 | $ | i — | $ | i 414 | $ | i — | |||||||||||||||
Foreign currency contracts | i 95 | i — | i 95 | i — | |||||||||||||||||||
Contingent consideration | i 14,556 | i — | i — | i 14,556 | |||||||||||||||||||
Total liabilities | $ | i 15,065 | $ | i — | $ | i 509 | $ | i 14,556 |
Basis of fair value measurement | |||||||||||||||||||||||
(in millions) | Total | Quoted prices in
active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | |||||||||||||||||||
Assets | |||||||||||||||||||||||
Cash and equivalents | $ | i 9,746 | $ | i 4,451 | $ | i 5,295 | $ | i — | |||||||||||||||
Money market funds and time deposits | i 45 | i — | i 45 | i — | |||||||||||||||||||
Debt securities | i 46 | i — | i 46 | i — | |||||||||||||||||||
Equity securities | i 121 | i 100 | i 21 | i — | |||||||||||||||||||
Interest rate swap contracts | i 26 | i — | i 26 | i — | |||||||||||||||||||
Foreign currency contracts | i 241 | i — | i 241 | i — | |||||||||||||||||||
Total assets | $ | i 10,225 | $ | i 4,551 | $ | i 5,674 | $ | i — | |||||||||||||||
Liabilities | |||||||||||||||||||||||
Interest rate swap contracts | $ | i 22 | $ | i — | $ | i 22 | $ | i — | |||||||||||||||
Foreign currency contracts | i 15 | i — | i 15 | i — | |||||||||||||||||||
Contingent consideration | i 14,887 | i — | i — | i 14,887 | |||||||||||||||||||
Total liabilities | $ | i 14,924 | $ | i — | $ | i 37 | $ | i 14,887 |
2022 Form 10-Q | | 14 |
September 30, 2022 | December 31, 2021 | ||||||||||||||||
(in millions) | Range | Weighted
average(a) | Range | Weighted average(a) | |||||||||||||
Discount rate | i 4.1% - i 5.5% | i 5.0% | i 0.2%-
i 2.6% | i 1.7% | |||||||||||||
Probability of payment for unachieved milestones | i 89% - i 100% | i 91% | i 89%
- i 100% | i 90% | |||||||||||||
Probability
of payment for royalties by indication(b) | i 56% - i 100% | i 98% | i 56%
- i 100% | i 96% | |||||||||||||
Projected year of payments | i 2022 - i 2034 | i 2027 | i 2022
- i 2034 | i 2027 |
Nine
months ended September 30, | ||||||||||||||
(in millions) | 2022 | 2021 | ||||||||||||
Beginning balance | $ | i 14,887 | $ | i 12,997 | ||||||||||
Change in fair value recognized in net earnings | i 647 | i 2,447 | ||||||||||||
Payments | ( i 978) | ( i 525) | ||||||||||||
Ending balance | $ | i 14,556 | $ | i 14,919 |
Basis of fair value measurement | ||||||||||||||||||||||||||
(in millions) | Book value | Approximate fair value | Quoted prices in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | |||||||||||||||||||||
Liabilities | ||||||||||||||||||||||||||
Short-term borrowings | $ | i 10 | $ | i 10 | $ | i — | $ | i 10 | $ | i — | ||||||||||||||||
Current portion of long-term debt and finance lease obligations, excluding fair value hedges | i 9,215 | i 9,191 | i 9,071 | i 120 | i — | |||||||||||||||||||||
Long-term debt and finance lease obligations, excluding fair value hedges | i 60,740 | i 53,834 | i 53,093 | i 741 | i — | |||||||||||||||||||||
Total liabilities | $ | i 69,965 | $ | i 63,035 | $ | i 62,164 | $ | i 871 | $ | i — |
2022
Form 10-Q | | 15 |
Basis of fair value measurement | ||||||||||||||||||||||||||
(in millions) | Book value | Approximate fair value | Quoted prices in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | |||||||||||||||||||||
Liabilities | ||||||||||||||||||||||||||
Short-term borrowings | $ | i 14 | $ | i 14 | $ | i — | $ | i 14 | $ | i — | ||||||||||||||||
Current portion of long-term debt and finance lease obligations, excluding fair value hedges | i 12,455 | i 11,830 | i 11,329 | i 501 | i — | |||||||||||||||||||||
Long-term debt and finance lease obligations, excluding fair value hedges | i 64,113 | i 71,810 | i 70,757 | i 1,053 | i — | |||||||||||||||||||||
Total liabilities | $ | i 76,582 | $ | i 83,654 | $ | i 82,086 | $ | i 1,568 | $ | i — |
2022 Form 10-Q | | 16 |
Defined
benefit plans | Other post- employment plans | ||||||||||||||||||||||||||||||||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||||||||||||||||||
Service cost | $ | i 113 | $ | i 110 | $ | i 342 | $ | i 331 | $ | i 13 | $ | i 12 | $ | i 38 | $ | i 36 | |||||||||||||||||||||||||||||||
Interest cost | i 74 | i 59 | i 223 | i 177 | i 6 | i 5 | i 18 | i 14 | |||||||||||||||||||||||||||||||||||||||
Expected return on plan assets | ( i 177) | ( i 166) | ( i 536) | ( i 498) | i — | i — | i — | i — | |||||||||||||||||||||||||||||||||||||||
Amortization of prior service cost (credit) | i 1 | i 1 | i 2 | i 2 | ( i 10) | ( i 10) | ( i 29) | ( i 29) | |||||||||||||||||||||||||||||||||||||||
Amortization of actuarial loss | i 57 | i 72 | i 173 | i 217 | i 7 | i 8 | i 20 | i 24 | |||||||||||||||||||||||||||||||||||||||
Net periodic benefit cost | $ | i 68 | $ | i 76 | $ | i 204 | $ | i 229 | $ | i 16 | $ | i 15 | $ | i 47 | $ | i 45 |
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Cost of products sold | $ | i 8 | $ | i 9 | $ | i 33 | $ | i 39 | ||||||||||||||||||
Research and development | i 47 | i 47 | i 194 | i 181 | ||||||||||||||||||||||
Selling, general and administrative | i 71 | i 79 | i 312 | i 343 | ||||||||||||||||||||||
Pre-tax compensation expense | i 126 | i 135 | i 539 | i 563 | ||||||||||||||||||||||
Tax benefit | i 25 | i 27 | i 102 | i 101 | ||||||||||||||||||||||
After-tax compensation expense | $ | i 101 | $ | i 108 | $ | i 437 | $ | i 462 |
2022 Form 10-Q
| | 17 |
2022 | 2021 | |||||||||||||||||||||||||||||||
Date Declared | Payment Date | Dividend Per Share | Date Declared | Payment Date | Dividend Per Share | |||||||||||||||||||||||||||
10/28/22 | 02/15/23 | $ | i 1.48 | 10/29/21 | 02/15/22 | $ | i 1.41 | |||||||||||||||||||||||||
09/09/22 | 11/15/22 | $ | i 1.41 | 09/10/21 | 11/15/21 | $ | i 1.30 | |||||||||||||||||||||||||
06/23/22 | 08/15/22 | $ | i 1.41 | 06/17/21 | 08/16/21 | $ | i 1.30 | |||||||||||||||||||||||||
02/17/22 | 05/16/22 | $ | i 1.41 | 02/18/21 | 05/14/21 | $ | i 1.30 |
(in millions) | Foreign
currency translation adjustments | Net investment hedging activities | Pension and post-employment benefits | Cash flow hedging activities | Total | ||||||||||||||||||||||||||||||
Balance as of December 31, 2021 | $ | ( i 570) | $ | ( i 91) | $ | ( i 2,546) | $ | i 308 | $ | ( i 2,899) | |||||||||||||||||||||||||
Other comprehensive income (loss) before reclassifications | ( i 2,043) | i 1,318 | i 6 | i 151 | ( i 568) | ||||||||||||||||||||||||||||||
Net losses (gains) reclassified from accumulated other comprehensive loss | i — | ( i 53) | i 130 | ( i 53) | i 24 | ||||||||||||||||||||||||||||||
Net current-period other comprehensive income (loss) | ( i 2,043) | i 1,265 | i 136 | i 98 | ( i 544) | ||||||||||||||||||||||||||||||
Balance as of September 30, 2022 | $ | ( i 2,613) | $ | i 1,174 | $ | ( i 2,410) | $ | i 406 | $ | ( i 3,443) |
(in millions) | Foreign
currency translation adjustments | Net investment hedging activities | Pension and post-employment benefits | Cash flow hedging activities | Total | ||||||||||||||||||||||||||||||
Balance as of December 31, 2020 | $ | i 583 | $ | ( i 790) | $ | ( i 3,067) | $ | i 157 | $ | ( i 3,117) | |||||||||||||||||||||||||
Other comprehensive income (loss) before reclassifications | ( i 794) | i 457 | i 27 | i 60 | ( i 250) | ||||||||||||||||||||||||||||||
Net losses (gains) reclassified from accumulated other comprehensive loss | i — | ( i 13) | i 169 | i 55 | i 211 | ||||||||||||||||||||||||||||||
Net current-period other comprehensive income (loss) | ( i 794) | i 444 | i 196 | i 115 | ( i 39) | ||||||||||||||||||||||||||||||
Balance as of September 30, 2021 | $ | ( i 211) | $ | ( i 346) | $ | ( i 2,871) | $ | i 272 | $ | ( i 3,156) |
2022 Form 10-Q | | 18 |
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||
(in millions) (brackets denote gains) | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Net investment hedging activities | |||||||||||||||||||||||
Gains on derivative amount excluded from effectiveness testing(a) | $ | ( i 29) | $ | ( i 7) | $ | ( i 67) | $ | ( i 16) | |||||||||||||||
Tax expense | i 6 | i 1 | i 14 | i 3 | |||||||||||||||||||
Total reclassifications, net of tax | $ | ( i 23) | $ | ( i 6) | $ | ( i 53) | $ | ( i 13) | |||||||||||||||
Pension and post-employment benefits | |||||||||||||||||||||||
Amortization of actuarial losses and other(b) | $ | i 55 | $ | i 71 | $ | i 166 | $ | i 214 | |||||||||||||||
Tax benefit | ( i 12) | ( i 15) | ( i 36) | ( i 45) | |||||||||||||||||||
Total reclassifications, net of tax | $ | i 43 | $ | i 56 | $ | i 130 | $ | i 169 | |||||||||||||||
Cash flow hedging activities | |||||||||||||||||||||||
Losses (gains) on foreign currency forward exchange contracts(c) | $ | ( i 21) | $ | i 28 | $ | ( i 47) | $ | i 62 | |||||||||||||||
Gains
on treasury rate lock agreements(a) | ( i 6) | ( i 6) | ( i 18) | ( i 18) | |||||||||||||||||||
Losses
on interest rate swap contracts(a) | i — | i 6 | i 3 | i 20 | |||||||||||||||||||
Tax expense (benefit) | i 4 | ( i 4) | i 9 | ( i 9) | |||||||||||||||||||
Total reclassifications, net of tax | $ | ( i 23) | $ | i 24 | $ | ( i 53) | $ | i 55 |
2022
Form 10-Q | | 19 |
2022 Form 10-Q | | 20 |
2022 Form 10-Q | | 21 |
2022
Form 10-Q | | 22 |
Three
months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Immunology | ||||||||||||||||||||||||||
Humira | United States | $ | i 4,956 | $ | i 4,613 | $ | i 13,613 | $ | i 12,777 | |||||||||||||||||
International | i 603 | i 812 | i 2,045 | i 2,583 | ||||||||||||||||||||||
Total | $ | i 5,559 | $ | i 5,425 | $ | i 15,658 | $ | i 15,360 | ||||||||||||||||||
Skyrizi | United States | $ | i 1,221 | $ | i 679 | $ | i 3,081 | $ | i 1,725 | |||||||||||||||||
International | i 176 | i 117 | i 508 | i 319 | ||||||||||||||||||||||
Total | $ | i 1,397 | $ | i 796 | $ | i 3,589 | $ | i 2,044 | ||||||||||||||||||
Rinvoq | United States | $ | i 505 | $ | i 348 | $ | i 1,228 | $ | i 889 | |||||||||||||||||
International | i 190 | i 105 | i 524 | i 245 | ||||||||||||||||||||||
Total | $ | i 695 | $ | i 453 | $ | i 1,752 | $ | i 1,134 | ||||||||||||||||||
Hematologic Oncology | ||||||||||||||||||||||||||
Imbruvica | United States | $ | i 849 | $ | i 1,109 | $ | i 2,585 | $ | i 3,207 | |||||||||||||||||
Collaboration revenues | i 286 | i 265 | i 868 | i 816 | ||||||||||||||||||||||
Total | $ | i 1,135 | $ | i 1,374 | $ | i 3,453 | $ | i 4,023 | ||||||||||||||||||
Venclexta | United States | $ | i 259 | $ | i 237 | $ | i 740 | $ | i 685 | |||||||||||||||||
International | i 256 | i 255 | i 753 | i 647 | ||||||||||||||||||||||
Total | $ | i 515 | $ | i 492 | $ | i 1,493 | $ | i 1,332 | ||||||||||||||||||
Aesthetics | ||||||||||||||||||||||||||
Botox Cosmetic | United States | $ | i 370 | $ | i 356 | $ | i 1,232 | $ | i 1,027 | |||||||||||||||||
International | i 267 | i 189 | i 741 | i 579 | ||||||||||||||||||||||
Total | $ | i 637 | $ | i 545 | $ | i 1,973 | $ | i 1,606 | ||||||||||||||||||
Juvederm Collection | United States | $ | i 125 | $ | i 159 | $ | i 420 | $ | i 478 | |||||||||||||||||
International | i 227 | i 195 | i 686 | i 625 | ||||||||||||||||||||||
Total | $ | i 352 | $ | i 354 | $ | i 1,106 | $ | i 1,103 | ||||||||||||||||||
Other Aesthetics | United States | $ | i 265 | $ | i 305 | $ | i 837 | $ | i 968 | |||||||||||||||||
International | i 47 | i 47 | i 130 | i 149 | ||||||||||||||||||||||
Total | $ | i 312 | $ | i 352 | $ | i 967 | $ | i 1,117 | ||||||||||||||||||
Neuroscience | ||||||||||||||||||||||||||
Botox Therapeutic | United States | $ | i 584 | $ | i 534 | $ | i 1,641 | $ | i 1,451 | |||||||||||||||||
International | i 115 | i 111 | i 350 | i 329 | ||||||||||||||||||||||
Total | $ | i 699 | $ | i 645 | $ | i 1,991 | $ | i 1,780 | ||||||||||||||||||
Vraylar
| United States | $ | i 554 | $ | i 461 | $ | i 1,473 | $ | i 1,239 | |||||||||||||||||
Duodopa | United States | $ | i 22 | $ | i 23 | $ | i 72 | $ | i 73 | |||||||||||||||||
International | i 88 | i 104 | i 279 | i 310 | ||||||||||||||||||||||
Total | $ | i 110 | $ | i 127 | $ | i 351 | $ | i 383 | ||||||||||||||||||
Ubrelvy | United States | $ | i 160 | $ | i 162 | $ | i 483 | $ | i 369 | |||||||||||||||||
Qulipta | United States | $ | i 62 | $ | i — | $ | i 106 | $ | i — | |||||||||||||||||
Other Neuroscience | United States | $ | i 82 | $ | i 166 | $ | i 400 | $ | i 489 | |||||||||||||||||
International | i 5 | i 5 | i 14 | i 13 | ||||||||||||||||||||||
Total | $ | i 87 | $ | i 171 | $ | i 414 | $ | i 502 |
2022
Form 10-Q | | 23 |
Three
months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Eye Care | ||||||||||||||||||||||||||
Lumigan/Ganfort | United States | $ | i 59 | $ | i 63 | $ | i 186 | $ | i 201 | |||||||||||||||||
International | i 62 | i 75 | i 205 | i 229 | ||||||||||||||||||||||
Total | $ | i 121 | $ | i 138 | $ | i 391 | $ | i 430 | ||||||||||||||||||
Alphagan/Combigan | United States | $ | i 37 | $ | i 89 | $ | i 161 | $ | i 271 | |||||||||||||||||
International | i 36 | i 39 | i 111 | i 117 | ||||||||||||||||||||||
Total | $ | i 73 | $ | i 128 | $ | i 272 | $ | i 388 | ||||||||||||||||||
Restasis | United States | $ | i 132 | $ | i 305 | $ | i 518 | $ | i 884 | |||||||||||||||||
International | i 10 | i 14 | i 38 | i 42 | ||||||||||||||||||||||
Total | $ | i 142 | $ | i 319 | $ | i 556 | $ | i 926 | ||||||||||||||||||
Other Eye Care | United States | $ | i 134 | $ | i 128 | $ | i 400 | $ | i 375 | |||||||||||||||||
International | i 153 | i 158 | i 492 | i 488 | ||||||||||||||||||||||
Total | $ | i 287 | $ | i 286 | $ | i 892 | $ | i 863 | ||||||||||||||||||
Other Key Products | ||||||||||||||||||||||||||
Mavyret | United States | $ | i 190 | $ | i 183 | $ | i 562 | $ | i 557 | |||||||||||||||||
International | i 193 | i 243 | i 599 | i 726 | ||||||||||||||||||||||
Total | $ | i 383 | $ | i 426 | $ | i 1,161 | $ | i 1,283 | ||||||||||||||||||
Creon | United States | $ | i 336 | $ | i 310 | $ | i 941 | $ | i 864 | |||||||||||||||||
Linzess/Constella | United States | $ | i 262 | $ | i 253 | $ | i 742 | $ | i 728 | |||||||||||||||||
International | i 9 | i 8 | i 24 | i 23 | ||||||||||||||||||||||
Total | $ | i 271 | $ | i 261 | $ | i 766 | $ | i 751 | ||||||||||||||||||
All other | $ | i 925 | $ | i 1,117 | $ | i 3,145 | $ | i 3,814 | ||||||||||||||||||
Total net revenues | $ | i 14,812 | $ | i 14,342 | $ | i 42,933 | $ | i 41,311 |
2022
Form 10-Q | | 24 |
2022 Form 10-Q | | 25 |
2022 Form 10-Q | | 26 |
2022 Form 10-Q | | 27 |
2022
Form 10-Q | | 28 |
Three
months ended September 30, | Percent change | Nine months ended September 30, | Percent change | |||||||||||||||||||||||||||||||||||||||||||||||
At actual currency rates | At constant currency rates | At actual currency rates | At constant currency rates | |||||||||||||||||||||||||||||||||||||||||||||||
(dollars
in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||||||||||||||||||||||||||
United States | $ | 11,763 | $ | 11,279 | 4.3 | % | 4.3 | % | $ | 33,521 | $ | 31,833 | 5.3 | % | 5.3 | % | ||||||||||||||||||||||||||||||||||
International | 3,049 | 3,063 | (0.4) | % | 9.6 | % | 9,412 | 9,478 | (0.7) | % | 6.7 | % | ||||||||||||||||||||||||||||||||||||||
Net
revenues | $ | 14,812 | $ | 14,342 | 3.3 | % | 5.4 | % | $ | 42,933 | $ | 41,311 | 3.9 | % | 5.6 | % |
2022
Form 10-Q | | 29 |
Three
months ended September 30, | Percent change | Nine months ended September 30, | Percent change | ||||||||||||||||||||||||||||||||||||||||||||||||||
At actual currency rates | At constant currency rates | At actual currency rates | At constant currency rates | ||||||||||||||||||||||||||||||||||||||||||||||||||
(dollars in millions) | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||
Immunology | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Humira | United States | $ | 4,956 | $ | 4,613 | 7.4 | % | 7.4 | % | $ | 13,613 | $ | 12,777 | 6.5 | % | 6.5 | % | ||||||||||||||||||||||||||||||||||||
International | 603 | 812 | (25.9) | % | (16.8) | % | 2,045 | 2,583 | (20.9) | % | (14.3) | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 5,559 | $ | 5,425 | 2.5 | % | 3.9 | % | $ | 15,658 | $ | 15,360 | 1.9 | % | 3.0 | % | |||||||||||||||||||||||||||||||||||||
Skyrizi | United States | $ | 1,221 | $ | 679 | 79.8 | % | 79.8 | % | $ | 3,081 | $ | 1,725 | 78.6 | % | 78.6 | % | ||||||||||||||||||||||||||||||||||||
International | 176 | 117 | 50.1 | % | 70.0 | % | 508 | 319 | 59.3 | % | 75.1 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 1,397 | $ | 796 | 75.4 | % | 78.3 | % | $ | 3,589 | $ | 2,044 | 75.6 | % | 78.1 | % | |||||||||||||||||||||||||||||||||||||
Rinvoq | United States | $ | 505 | $ | 348 | 44.7 | % | 44.7 | % | $ | 1,228 | $ | 889 | 38.0 | % | 38.0 | % | ||||||||||||||||||||||||||||||||||||
International | 190 | 105 | 82.9 | % | >100.0 % | 524 | 245 | >100.0 % | >100.0 % | ||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 695 | $ | 453 | 53.5 | % | 59.3 | % | $ | 1,752 | $ | 1,134 | 54.5 | % | 59.3 | % | |||||||||||||||||||||||||||||||||||||
Hematologic Oncology | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Imbruvica | United States | $ | 849 | $ | 1,109 | (23.5) | % | (23.5) | % | $ | 2,585 | $ | 3,207 | (19.4) | % | (19.4) | % | ||||||||||||||||||||||||||||||||||||
Collaboration revenues | 286 | 265 | 7.6 | % | 7.6 | % | 868 | 816 | 6.3 | % | 6.3 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 1,135 | $ | 1,374 | (17.4) | % | (17.4) | % | $ | 3,453 | $ | 4,023 | (14.2) | % | (14.2) | % | |||||||||||||||||||||||||||||||||||||
Venclexta | United States | $ | 259 | $ | 237 | 9.2 | % | 9.2 | % | $ | 740 | $ | 685 | 8.1 | % | 8.1 | % | ||||||||||||||||||||||||||||||||||||
International | 256 | 255 | 0.1 | % | 13.2 | % | 753 | 647 | 16.2 | % | 27.3 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 515 | $ | 492 | 4.5 | % | 11.3 | % | $ | 1,493 | $ | 1,332 | 12.1 | % | 17.5 | % | |||||||||||||||||||||||||||||||||||||
Aesthetics | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Botox Cosmetic | United States | $ | 370 | $ | 356 | 4.1 | % | 4.1 | % | $ | 1,232 | $ | 1,027 | 20.0 | % | 20.0 | % | ||||||||||||||||||||||||||||||||||||
International | 267 | 189 | 41.0 | % | 54.5 | % | 741 | 579 | 27.9 | % | 36.8 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 637 | $ | 545 | 16.9 | % | 21.6 | % | $ | 1,973 | $ | 1,606 | 22.8 | % | 26.0 | % | |||||||||||||||||||||||||||||||||||||
Juvederm Collection | United States | $ | 125 | $ | 159 | (21.9) | % | (21.9) | % | $ | 420 | $ | 478 | (12.3) | % | (12.3) | % | ||||||||||||||||||||||||||||||||||||
International | 227 | 195 | 16.9 | % | 27.7 | % | 686 | 625 | 9.9 | % | 17.6 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 352 | $ | 354 | (0.6) | % | 5.3 | % | $ | 1,106 | $ | 1,103 | 0.3 | % | 4.6 | % | |||||||||||||||||||||||||||||||||||||
Other Aesthetics | United States | $ | 265 | $ | 305 | (13.1) | % | (13.1) | % | $ | 837 | $ | 968 | (13.4) | % | (13.4) | % | ||||||||||||||||||||||||||||||||||||
International | 47 | 47 | (0.8) | % | 8.3 | % | 130 | 149 | (12.8) | % | (7.2) | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 312 | $ | 352 | (11.4) | % | (10.2) | % | $ | 967 | $ | 1,117 | (13.4) | % | (12.7) | % | |||||||||||||||||||||||||||||||||||||
Neuroscience | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Botox Therapeutic | United States | $ | 584 | $ | 534 | 9.2 | % | 9.2 | % | $ | 1,641 | $ | 1,451 | 13.1 | % | 13.1 | % | ||||||||||||||||||||||||||||||||||||
International | 115 | 111 | 3.6 | % | 14.2 | % | 350 | 329 | 6.5 | % | 15.0 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 699 | $ | 645 | 8.2 | % | 10.0 | % | $ | 1,991 | $ | 1,780 | 11.9 | % | 13.5 | % | |||||||||||||||||||||||||||||||||||||
Vraylar | United States | $ | 554 | $ | 461 | 20.1 | % | 20.1 | % | $ | 1,473 | $ | 1,239 | 18.9 | % | 18.9 | % | ||||||||||||||||||||||||||||||||||||
Duodopa | United States | $ | 22 | $ | 23 | (4.9) | % | (4.9) | % | $ | 72 | $ | 73 | (2.4) | % | (2.4) | % | ||||||||||||||||||||||||||||||||||||
International | 88 | 104 | (15.0) | % | (2.6) | % | 279 | 310 | (9.8) | % | — | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 110 | $ | 127 | (13.1) | % | (3.0) | % | $ | 351 | $ | 383 | (8.4) | % | (0.5) | % | |||||||||||||||||||||||||||||||||||||
Ubrelvy | United States | $ | 160 | $ | 162 | (1.4) | % | (1.4) | % | $ | 483 | $ | 369 | 31.0 | % | 31.0 | % | ||||||||||||||||||||||||||||||||||||
Qulipta | United States | $ | 62 | $ | — | n/m | n/m | $ | 106 | $ | — | n/m | n/m | ||||||||||||||||||||||||||||||||||||||||
Other Neuroscience | United States | $ | 82 | $ | 166 | (50.5) | % | (50.5) | % | $ | 400 | $ | 489 | (18.3) | % | (18.3) | % | ||||||||||||||||||||||||||||||||||||
International | 5 | 5 | 10.2 | % | 14.1 | % | 14 | 13 | 10.3 | % | 13.1 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 87 | $ | 171 | (49.0) | % | (48.9) | % | $ | 414 | $ | 502 | (17.6) | % | (17.5) | % |
2022
Form 10-Q | | 30 |
Three
months ended September 30, | Percent change | Nine months ended September 30, | Percent change | ||||||||||||||||||||||||||||||||||||||||||||||||||
At actual currency rates | At constant currency rates | At actual currency rates | At constant currency rates | ||||||||||||||||||||||||||||||||||||||||||||||||||
(dollars in millions) | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||
Eye Care | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Lumigan/Ganfort | United States | $ | 59 | $ | 63 | (4.4) | % | (4.4) | % | $ | 186 | $ | 201 | (7.1) | % | (7.1) | % | ||||||||||||||||||||||||||||||||||||
International | 62 | 75 | (18.7) | % | (8.7) | % | 205 | 229 | (10.8) | % | (2.9) | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 121 | $ | 138 | (12.2) | % | (6.7) | % | $ | 391 | $ | 430 | (9.0) | % | (4.8) | % | |||||||||||||||||||||||||||||||||||||
Alphagan/Combigan | United States | $ | 37 | $ | 89 | (58.2) | % | (58.2) | % | $ | 161 | $ | 271 | (40.8) | % | (40.8) | % | ||||||||||||||||||||||||||||||||||||
International | 36 | 39 | (8.9) | % | 2.9 | % | 111 | 117 | (5.1) | % | 4.9 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 73 | $ | 128 | (43.0) | % | (39.4) | % | $ | 272 | $ | 388 | (30.0) | % | (27.0) | % | |||||||||||||||||||||||||||||||||||||
Restasis | United States | $ | 132 | $ | 305 | (56.7) | % | (56.7) | % | $ | 518 | $ | 884 | (41.3) | % | (41.3) | % | ||||||||||||||||||||||||||||||||||||
International | 10 | 14 | (30.7) | % | (37.7) | % | 38 | 42 | (10.1) | % | (2.8) | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 142 | $ | 319 | (55.6) | % | (55.9) | % | $ | 556 | $ | 926 | (39.9) | % | (39.6) | % | |||||||||||||||||||||||||||||||||||||
Other Eye Care | United States | $ | 134 | $ | 128 | 3.7 | % | 3.7 | % | $ | 400 | $ | 375 | 6.3 | % | 6.3 | % | ||||||||||||||||||||||||||||||||||||
International | 153 | 158 | (2.7) | % | 9.1 | % | 492 | 488 | 0.9 | % | 10.1 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 287 | $ | 286 | 0.1 | % | 6.6 | % | $ | 892 | $ | 863 | 3.3 | % | 8.5 | % | |||||||||||||||||||||||||||||||||||||
Other Key Products | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Mavyret | United States | $ | 190 | $ | 183 | 3.5 | % | 3.5 | % | $ | 562 | $ | 557 | 0.9 | % | 0.9 | % | ||||||||||||||||||||||||||||||||||||
International | 193 | 243 | (20.6) | % | (10.3) | % | 599 | 726 | (17.5) | % | (9.1) | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 383 | $ | 426 | (10.2) | % | (4.4) | % | $ | 1,161 | $ | 1,283 | (9.5) | % | (4.7) | % | |||||||||||||||||||||||||||||||||||||
Creon | United States | $ | 336 | $ | 310 | 8.5 | % | 8.5 | % | $ | 941 | $ | 864 | 9.0 | % | 9.0 | % | ||||||||||||||||||||||||||||||||||||
Linzess/Constella | United States | $ | 262 | $ | 253 | 3.4 | % | 3.4 | % | $ | 742 | $ | 728 | 2.0 | % | 2.0 | % | ||||||||||||||||||||||||||||||||||||
International | 9 | 8 | 16.0 | % | 25.8 | % | 24 | 23 | 3.2 | % | 9.6 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 271 | $ | 261 | 3.8 | % | 4.1 | % | $ | 766 | $ | 751 | 2.0 | % | 2.2 | % | |||||||||||||||||||||||||||||||||||||
All other | $ | 925 | $ | 1,117 | (16.8) | % | (15.3) | % | $ | 3,145 | $ | 3,814 | (17.5) | % | (16.3) | % | |||||||||||||||||||||||||||||||||||||
Total net revenues | $ | 14,812 | $ | 14,342 | 3.3 | % | 5.4 | % | $ | 42,933 | $ | 41,311 | 3.9 | % | 5.6 | % |
2022 Form 10-Q | | 31 |
Three
months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||||||||||||||
(dollars in millions) | 2022 | 2021 | % change | 2022 | 2021 | % change | ||||||||||||||||||||||||||||||||
Gross margin | $ | 9,790 | $ | 9,952 | (2) | % | $ | 29,689 | $ | 28,185 | 5 | % | ||||||||||||||||||||||||||
as a % of net revenues | 66 | % | 69 | % | 69 | % | 68 | % |
Three
months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||||||||||||||
(dollars in millions) | 2022 | 2021 | % change | 2022 | 2021 | % change | ||||||||||||||||||||||||||||||||
Selling, general and administrative | $ | 3,304 | $ | 3,083 | 7 | % | $ | 11,843 | $ | 9,089 | 30 | % | ||||||||||||||||||||||||||
as a % of net revenues | 22 | % | 21 | % | 28 | % | 22 | % |
2022 Form 10-Q | | 32 |
Three months ended September 30, | Nine
months ended September 30, | |||||||||||||||||||||||||||||||||||||
(dollars in millions) | 2022 | 2021 | % change | 2022 | 2021 | % change | ||||||||||||||||||||||||||||||||
Research and development | $ | 1,614 | $ | 1,661 | (3) | % | $ | 4,720 | $ | 5,095 | (7) | % | ||||||||||||||||||||||||||
as a % of net revenues | 11 | % | 12 | % | 11 | % | 12 | % | ||||||||||||||||||||||||||||||
Acquired IPR&D and milestones | $ | 40 | $ | 402 | (90) | % | $ | 454 | $ | 719 | (37) | % |
Three
months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Interest expense | $ | 560 | $ | 596 | $ | 1,664 | $ | 1,843 | ||||||||||||||||||
Interest income | (63) | (11) | (96) | (30) | ||||||||||||||||||||||
Interest expense, net | $ | 497 | $ | 585 | $ | 1,568 | $ | 1,813 | ||||||||||||||||||
Net foreign exchange loss | $ | 36 | $ | 12 | $ | 108 | $ | 35 | ||||||||||||||||||
Other expense (income), net | (330) | 21 | 427 | 2,284 |
2022 Form 10-Q
| | 33 |
Nine months ended September 30, | |||||||||||
(in millions) | 2022 | 2021 | |||||||||
Cash flows provided by (used in): | |||||||||||
Operating activities | $ | 17,515 | $ | 17,702 | |||||||
Investing activities | (175) | (1,199) | |||||||||
Financing activities | (15,169) | (12,701) |
2022 Form 10-Q | | 34 |
2022
Form 10-Q | | 35 |
2022 Form 10-Q | | 36 |
Period | (a) Total
Number of Shares (or Units) Purchased | (b) Average Price Paid per Share (or Unit) | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs | ||||||||||||||||||||||
July 1, 2022 - July 31, 2022 | 893 | (1) | $152.92 | (1) | — | $1,393,714,917 | ||||||||||||||||||||
August 1, 2022 - August 30, 2022 | 1,023 | (1) | $140.00 | (1) | — | $1,393,714,917 | ||||||||||||||||||||
September 1, 2022 - September 30, 2022 | 1,052 | (1) | $137.87 | (1) | — | $1,393,714,917 | ||||||||||||||||||||
Total | 2,968 | (1) | $143.13 | (1) | — | $1,393,714,917 |
2022 Form 10-Q | | 37 |
Exhibit No. | Exhibit Description | ||||||||||
101 | The
following financial statements and notes from the AbbVie Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 4, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Earnings; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v) Condensed Consolidated Statements of Cash Flows; and (vi) the Notes to Condensed Consolidated Financial Statements. | ||||||||||
104 | Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101). |
2022
Form 10-Q | | 38 |
ABBVIE INC. | ||||||||
By: | /s/ Scott T. Reents | |||||||
Scott T. Reents | ||||||||
Senior Vice President, | ||||||||
Chief Financial Officer (Principal Financial Officer) |
2022 Form 10-Q | | 39 |
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
2/15/23 | ||||
1/13/23 | ||||
11/15/22 | ||||
Filed on: | 11/4/22 | |||
10/28/22 | 8-K | |||
10/26/22 | ||||
10/14/22 | 8-K | |||
For Period end: | 9/30/22 | 4 | ||
9/9/22 | ||||
9/1/22 | ||||
8/30/22 | ||||
8/1/22 | ||||
7/31/22 | ||||
7/1/22 | ||||
6/30/22 | 10-Q, 4 | |||
3/31/22 | 10-Q, 4 | |||
12/31/21 | 10-K, 11-K, 4, SD | |||
9/30/21 | 10-Q, 4 | |||
8/30/21 | ||||
6/30/21 | 10-Q, 4 | |||
12/31/20 | 10-K, 11-K, 4, 8-K, SD | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/20/24 AbbVie Inc. 10-K 12/31/23 118:19M 2/17/23 AbbVie Inc. 10-K 12/31/22 120:24M 11/04/22 AbbVie Inc. S-8 11/04/22 4:106K Toppan Merrill/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/14/22 AbbVie Inc. 8-K:5,9 10/12/22 13:725K Toppan Merrill/FA |